

# Rotavirus Infections (Infectious Disease) - Drugs In Development, 2021

<https://marketpublishers.com/r/R272A54A766CEN.html>

Date: August 2021

Pages: 65

Price: US\$ 2,000.00 (Single User License)

ID: R272A54A766CEN

## Abstracts

Rotavirus Infections (Infectious Disease) - Drugs In Development, 2021

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections - Drugs In Development, 2021, provides an overview of the Rotavirus Infections (Infectious Disease) pipeline landscape. Rotavirus is a virus that infects the bowels. Rotavirus is the most common cause of severe diarrhea among infants and children. Transmission of rotavirus most often occurs through fecal-oral contact. Usually, this occurs from poor hand washing or from ingestion of contaminated food or water. The virus may also be transmitted through the respiratory tract or by other body fluids, but these routes are less common. The virus may live on inanimate surfaces, such as doorknobs, toys, and hard surfaces. Symptoms may include severe diarrhea, vomiting, fever, and dehydration.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rotavirus Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Rotavirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Rotavirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 1, 6 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 1, 1, 1 and 1 molecules, respectively. Rotavirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Rotavirus Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Rotavirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Rotavirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Rotavirus Infections (Infectious Disease)

therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Rotavirus Infections (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Rotavirus Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Rotavirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

- Introduction
- Global Markets Direct Report Coverage
- Rotavirus Infections - Overview
- Rotavirus Infections - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Rotavirus Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Rotavirus Infections - Companies Involved in Therapeutics Development
- Aridis Pharmaceuticals Inc
- Beijing Minhai Biotechnology Co Ltd
- Bharat Biotech Ltd
- Blue Water Vaccines Inc
- Chongqing Zhifei Biological Products Co Ltd
- ConserV Bioscience Ltd
- Curevac NV
- GlaxoSmithKline Plc
- Hilleman Laboratories Pvt Ltd
- IGY Immune Technologies & Life Sciences Inc
- Medicago Inc
- Micron Biomedical Inc
- Serum Institute of India Pvt Ltd
- Symvivo Inc
- UMN Pharma Inc
- Wuhan Institute of Biological Products Co Ltd
- Yisheng Biopharma Co Ltd
- Rotavirus Infections - Drug Profiles
- (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile
- Product Description
- Mechanism Of Action

**R&D Progress**

(norovirus + rotavirus) vaccine - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

(rotavirus (virus like particle) + typhiod) vaccine - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

IGY-106 - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

poliomyelitis vaccine + rotavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

Rotavac-5C - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

rotavirus (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

rotavirus (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

rotavirus [Serotype P2] (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

**R&D Progress**

rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [serotypes G1, G2, G3, G4, P1(8)] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rotavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RV-3BB - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RV-625 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UMN-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rotavirus Infections - Dormant Projects

Rotavirus Infections - Product Development Milestones

Featured News & Press Releases

Mar 04, 2021: GSK makes landmark pricing agreement for rotavirus vaccine, Rotarix, for use with children living in humanitarian crises

Jun 03, 2019: Rotavirus vaccine (Rotarix): patient group direction (PGD) template

Jan 24, 2018: India-made rotavirus vaccine achieves World Health Organization prequalification

Sep 21, 2016: Batavia Biosciences receives grant to develop new vaccine against rotavirus

Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate

Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus

Apr 26, 2012: GSK's Rotarix To Be Introduced In Ghana

Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan

May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation



[Contact Us](#)  
[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Rotavirus Infections, 2021  
Number of Products under Development by Companies, 2021  
Number of Products under Development by Universities/Institutes, 2021  
Products under Development by Companies, 2021  
Products under Development by Universities/Institutes, 2021  
Number of Products by Stage and Target, 2021  
Number of Products by Stage and Mechanism of Action, 2021  
Number of Products by Stage and Route of Administration, 2021  
Number of Products by Stage and Molecule Type, 2021  
Rotavirus Infections - Pipeline by Aridis Pharmaceuticals Inc, 2021  
Rotavirus Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2021  
Rotavirus Infections - Pipeline by Bharat Biotech Ltd, 2021  
Rotavirus Infections - Pipeline by Blue Water Vaccines Inc, 2021  
Rotavirus Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2021  
Rotavirus Infections - Pipeline by ConserV Bioscience Ltd, 2021  
Rotavirus Infections - Pipeline by Curevac NV, 2021  
Rotavirus Infections - Pipeline by GlaxoSmithKline Plc, 2021  
Rotavirus Infections - Pipeline by Hilleman Laboratories Pvt Ltd, 2021  
Rotavirus Infections - Pipeline by IGY Immune Technologies & Life Sciences Inc, 2021  
Rotavirus Infections - Pipeline by Medicago Inc, 2021  
Rotavirus Infections - Pipeline by Micron Biomedical Inc, 2021  
Rotavirus Infections - Pipeline by Serum Institute of India Pvt Ltd, 2021  
Rotavirus Infections - Pipeline by Symvivo Inc, 2021  
Rotavirus Infections - Pipeline by UMN Pharma Inc, 2021  
Rotavirus Infections - Pipeline by Wuhan Institute of Biological Products Co Ltd, 2021  
Rotavirus Infections - Pipeline by Yisheng Biopharma Co Ltd, 2021  
Rotavirus Infections - Dormant Projects, 2021

## List Of Figures

### LIST OF FIGURES

- Number of Products under Development for Rotavirus Infections, 2021
- Number of Products under Development by Companies, 2021
- Number of Products under Development by Universities/Institutes, 2021
- Number of Products by Stage and Targets, 2021
- Number of Products by Stage and Mechanism of Actions, 2021
- Number of Products by Routes of Administration, 2021
- Number of Products by Stage and Routes of Administration, 2021
- Number of Products by Molecule Types, 2021
- Number of Products by Stage and Molecule Types, 2021

## I would like to order

Product name: Rotavirus Infections (Infectious Disease) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/R272A54A766CEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R272A54A766CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970